(Q50266474)

28 February 2018

title

Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy. (English)

1 reference

28 February 2018

attention deficit hyperactivity disorder

1 reference

1 reference

1 reference

1

1 reference

28 February 2018

author name string

Jane Whitney

2

1 reference

28 February 2018

Sneha Rao

3

1 reference

28 February 2018

Claire Tilley

4

1 reference

28 February 2018

Rachel Lobel

5

1 reference

28 February 2018

Joseph Gonzalez-Heydrich

6

1 reference

28 February 2018

publication date

13 December 2010

1 reference

28 February 2018

published in

Epilepsy Behavior

1 reference

28 February 2018

volume

20

1 reference

28 February 2018

issue

1

1 reference

28 February 2018

page(s)

95-102

1 reference

28 February 2018

Update on the epidemiology and prognosis of pediatric epilepsy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

The relationship of psychiatric illnesses and seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Psychiatric aspects of epileptic children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

The development of psychiatric disorder among schoolchildren with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Long-term psychosocial outcome in typical absence epilepsy. Sometimes a wolf in sheeps' clothing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Differential diagnosis and treatment of psychiatric disorders in children and adolescents with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

The frequency, complications and aetiology of ADHD in new onset paediatric epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Psychiatric disorders and behavioral characteristics of pediatric patients with both epilepsy and attention-deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Use of Methylphenidate for Attention-Deficit Hyperactivity Disorder in Patients With Epilepsy or Electroencephalographic Abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Acute Hepatic Failure Associated with the Use of Sodium Valproate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Seizures and prolonged QTc with atomoxetine overdose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Isolated atomoxetine overdose resulting in seizure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

The prevalence and incidence of convulsive disorders in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Acute atomoxetine effects on the EEG of children with attention-deficit/hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Commission on Outcome Measurement in Epilepsy, 1994-1997: final report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Proof of efficacy trials: endpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Seizure severity in children with epilepsy: a parent-completed scale compared with clinical data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Implementation of an electronic medical record system in a pediatric psychopharmacology program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

Severe liver injury after initiating therapy with atomoxetine in two children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.11.002

10.1016/J.YEBEH.2010.11.002

7 January 2021

Identifiers

DOI

1 reference

28 February 2018

PubMed ID

21146461

1 reference

28 February 2018